United States Patent 6,417,175: Scope and Claims Map, Claim Coverage Boundaries, and US Patent Landscape for the Cef... Cephem Thiophene/Thiazole-Linked Phosphonoamino Cephalosporin Class
United States Patent US 6,417,175 is drafted around a cephem (cephalosporin) core substituted at the 7β-position with an ethoxyimino acetamido linker and bearing a thiazolylthio substituent plus a phosphonoamino-1,2,4-thiadiazole motif, where the “inventive spine” is claim 1’s formula, with narrower dependent coverage to specific positional and substitution variants and to pharmaceutical compositions and infection-treatment methods (including MRSA).
What compounds are protected by US 6,417,175 (claim 1 formula), and what is the practical scope?
Short answer: Claim 1 protects a genus of phosphonoamino-1,2,4-thiadiazole-cephem cephalosporin salts and free bases where key structural elements are fixed:
- R1 is a phosphono group
- Y is S
- one of R3/R4 is a substituted pyridinium and the other is H or hydrocarbyl, or R3+R4 can cyclize into a quaternized N-containing ring
- n is 0 or 1 (controls whether the Q/X/Y linkage includes an additional ring atom in the general formula)
- The cephem substitution pattern is consistent with the specific example claims (claim 2/4).
Claim 1: genus boundaries you can enforce on paper
From the claim text you provided, claim 1 requires the following non-negotiable structural constraints:
Core scaffold
- A cephem (cephalosporin) ring system appears in the detailed embodiments (claims 2 and 4), and the genus formula in claim 1 is consistent with a 3-substituted, 7β-substituted cephem.
R1 phosphono group
- R1 is a phosphono group. This is a major scoping handle: replacement of the phosphono substituent with another anionic group (carboxylate, sulfonate, phosphinate variant, prodrug ester) risks moving outside the literal claim.
Y is S
- Y is S fixes the presence of a sulfur-containing connection in the heteroatom linkage of the formula.
n is 0 or 1
- This controls a specific element in the formula (typically a methylene/atom count or ring-atom participation in the general structure). If a competitor alters the atom count corresponding to “n”, that can narrow literal coverage quickly.
Q and X
- Each of Q and X is either nitrogen (N) or CH. This makes the genus depend on whether the corresponding positions are N-containing or carbon.
R3/R4: pyridinium requirement
- “One of R3 and R4 is a pyridinium group… the other is a hydrogen atom or hydrocarbon group… or R3 and R4 taken together may form a quaternized nitrogen-containing heterocyclic ring.”
- Practically, this means the structure must include:
- a quaternized pyridinium moiety, either as a substituent at the relevant position, or
- a fused/cyclized quaternized ring formed by R3+R4.
What claim 1 does not plainly cover
Based only on your claim text, these substitutions are likely outside literal claim 1:
- Removing the phosphono group or converting it to a non-phosphono functionality not literally encompassed by “R1 is a phosphono group”.
- Replacing the pyridinium with a different permanently charged group (e.g., quaternary ammonium that is not pyridinium, or a morpholinium), unless that replacement is captured by “pyridinium group” language or by the “quaternized nitrogen-containing heterocyclic ring” alternative built from R3/R4.
- Changing Y away from S.
What specific compound embodiments are explicitly claimed in US 6,417,175 (claims 2 and 4, including the 7β cephem details)?
Short answer: Claim 2 and claim 4 lock in a specific named structure:
7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate and its salt.
Claim 2 locked structure (free base or general salt coverage)
- 7β-position: ethoxyimino acetamido substituent
- Linker substituent: 5-phosphonoamino-1,2,4-thiadiazole-3-yl
- 3-position thioether chain: 4-(1-methyl-4-pyridinio)-2-thiazolylthio
- Cephem: 3-cephem-4-carboxylate at the 4-position
Claim 4 is the same core but drafted as an explicit “compound of claim 1” variant
- Claim 4 repeats the same structure and covers either the compound or its salt.
Enforcement note: If a product matches this exact structure (or is a salt form that remains the same active compound), it hits claims 2/4 cleanly.
Are pharmaceutical compositions and dosing forms protected, and what does claim 17 cover?
Short answer: Yes. The patent claims standard composition coverage and manufacturing-by-mixing plus administration route limitations for certain methods.
Composition claims
- Claim 17: “A pharmaceutical composition containing the compound shown in claim 1” with pharmaceutically acceptable carrier/diluent/bulking agent.
- Claim 18: “A pharmaceutical composition containing the compound of claim 4” with pharmaceutically acceptable carrier/diluent/bulking agent.
- Claim 3 and 19: manufacturing/composition-production by mixing a compound of claim 1 or claim 4 with pharmaceutically acceptable carrier/diluent/bulking agent.
Injection administration (method claims)
- Claim 15: treatment method where the compound is administered by injection.
- Claim 20: same but for the compound of claim 4.
Practical scope: Unless the competitor uses a substantially different delivery mechanism that avoids the “administered by injection” method claim, they still face literal composition protection under claims 17/18 if the same active appears in a formulation.
What treatment methods are claimed, including MRSA?
Short answer: Claims 5–7 and 12, 16, 21 cover treating bacterial infections using effective amounts of claim 1/4 compound, with explicit coverage for MRSA.
Core method claims
- Claim 5: administering an effective amount of claim 1 compound to treat bacterial infection.
- Claim 6: administering claim 1 compound together with carriers/excipients.
- Claim 12: administering effective amount of claim 4 compound.
- Claim 16: administering claim 4 compound with carriers/excipients.
MRSA-specific dependency
- Claim 7: bacterial infection is MRSA (dependent on claim 5).
- Claim 21: bacterial infection is MRSA (dependent on claim 12).
Practical enforcement posture: For an accused infringer, MRSA indication dosing is a direct hook. If the product label or clinical use emphasizes MRSA and the same compound is used, method claims align.
What formulation and salt protection exists (and what’s the litigation risk if generics use different salts/prodrugs)?
Short answer: The patent includes explicit coverage for salts of claim 1 compounds and the specific ethoxyimino phosphonoamino cephem.
Salt and variant coverage
- Claim 1 ends with “or salt thereof.”
- Claim 4 explicitly covers “compound… or its salt.”
- Claim 2 is framed as a specific structure (typically the active) and does not remove salt coverage in your claim text, but the explicit “or salt” language is clearly in claim 1 and claim 4.
Prodrug risk
Your provided claim set does not show explicit “prodrug” language. If an accused product uses a phosphono prodrug (e.g., masking groups that hydrolyze in vivo), whether that stays within “R1 is a phosphono group” depends on whether the prodrug itself has a phosphono group literally and whether the claim reads on the prodrug structure. The literal claim text you supplied suggests the claim is structural to the phosphono group in the compound being administered.
How broad is claim 8–11 versus claim 2/4 (pyridinium substitution and Q/X/n limitations)?
Short answer: Claims 8–11 are narrower “feature selection” dependent claims that can strengthen validity against partial prior art and help establish infringement for sub-genus products.
Key dependent features
- Claim 8: R3 is pyridinium, R4 is H.
- Claim 9: Q is nitrogen.
- Claim 10: X is nitrogen.
- Claim 11: n is 0.
Practical effect: These help cover variants that might otherwise be argued outside claim 1’s general formula range. If an accused compound differs from the main embodiment, these dependencies may still pin them.
What specific variant is claimed in claim 13 (fluoromethoxyimino analogue)?
Short answer: Claim 13 explicitly claims an ethoxyimino analogue with a fluoromethoxyimino moiety:
- 7β-[2(Z)-fluoromethoxyimino-2-(5-phophonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate or its salt.
Practical scope shift: This locks a second chemical series variant around changing the oxime ether group at the 7β side chain, while keeping:
- phosphonoamino-thiadiazole motif,
- pyridinium-thiazole-thioether,
- cephem core.
What does claim 14 cover about making the compound (process/manufacturing IP)?
Short answer: Claim 14 claims a method for producing a compound of claim 1 by reacting two intermediate/precursor formulae.
Practical implications:
- If the process uses the same intermediate pairing and reaction conditions correspond to the claim’s structure-to-structure mapping, the method claim can provide leverage beyond formulation and composition.
- For generic or follow-on manufacturing, process design-arounds often focus on using different intermediates or alternative synthetic routes.
Your provided claim text for claim 14 includes placeholders for the intermediate formulae. Because the actual intermediate structures aren’t shown in your paste, only the existence of a process claim can be stated here.
What patent estate features can be inferred from this claim set for US exclusivity strategy?
Short answer: US 6,417,175 reads like a “core compound plus downstream practice” patent. It has:
- a structural genus claim (compound),
- specific exemplified active embodiments,
- composition and formulation “mixing” claims,
- administration route and dosing method claims,
- an MRSA use claim,
- additional chemical variant coverage (claim 13),
- a process claim (claim 14).
Business consequence: Even if a competitor designs around the exact compound, they may still face composition or method claims if they use the same active compound in a covered formulation and indication.
What does this claim scope suggest for generic entry risk and Paragraph IV strategy (US)?
Short answer: The strongest infringement hooks are:
- direct structural infringement of claim 1, and
- direct product matching of claims 2/4, plus
- method of treatment for MRSA (claims 7 and 21), plus
- composition inclusion (claims 17/18).
Likely infringement scenarios
-
ANDA with identical API (same active compound/salt form)
- Direct infringement of compound claims (1, 2, 4, 13 depending on which is used) if the marketed API matches.
- Indirect via labeling for MRSA can implicate method claims 5–7 and 12, 16, 21.
- Formulation likely hits claims 17/18 if the formulation is a standard mixture with acceptable carriers.
-
ANDAs with close structural analogs (changes to oxime ether, n/Q/X, or pyridinium substitution)
- Literal infringement depends on how those modifications map to the claim’s enumerated variables (R1, Y, Q/X, n, R3/R4).
- Dependent claims 8–11 and 13 can expand coverage to common “near miss” modifications.
-
Salt-only changes
- Claim 1 and 4 cover “salt thereof.” Switching salts may not avoid claim coverage unless the salt form is argued non-covered (not shown in your text).
Likely invalidity pressure points
Without the rest of the patent record and file history, only general levers can be inferred:
- Genus breadth tied to formula variables (Q/X/n and pyridinium substitution) may face prior-art anticipation if prior art discloses the same cephem-phosphono-pyridinium-thiazole motif with minor substitution changes.
- Variant claim 13 (fluoromethoxyimino) may inherit obviousness risks if closely related analogues exist in prior art.
Key Takeaways
- US 6,417,175 is a cephalosporin (cephem) genus + specific active embodiments patent focused on a phosphonoamino-1,2,4-thiadiazole substitution pattern and a pyridinium-containing thiazolylthio side chain.
- The compound claim 1 sets strong structural limits: phosphono group (R1), sulfur linkage (Y = S), Q/X = N or CH, n = 0 or 1, and a pyridinium/quaternized nitrogen-containing motif via R3/R4.
- Direct chemical coverage is explicit for:
- ethoxyimino active (claims 2 and 4),
- fluoromethoxyimino analogue (claim 13),
- plus dependent narrowing for pyridinium substitution and formula variables (claims 8–11).
- Downstream IP includes:
- composition by mixing (claims 3, 17, 19),
- treatment methods for bacterial infection including MRSA (claims 5–7, 12, 16, 21),
- injection administration variants (claims 15, 20),
- and a process for producing the compounds (claim 14).
FAQs
-
Does US 6,417,175 cover different salts of the active compound?
Claim 1 and claim 4 state “or salt thereof,” covering salts of the claimed compounds.
-
What changes would most likely avoid literal infringement of claim 1?
Alterations that remove or replace the required phosphono group (R1), change Y from S, or eliminate the pyridinium/quaternized nitrogen-containing motif tied to R3/R4.
-
Are MRSA indications explicitly covered?
Yes. Claims 7 (dependent on claim 5) and 21 (dependent on claim 12) specify MRSA.
-
Does the patent cover formulation manufacture and standard excipient mixing?
Yes. Claims 3 and 19 cover producing pharmaceutical compositions by mixing the compound with pharmaceutically acceptable carriers/diluents/bulking agents; claims 17 and 18 cover composition itself.
-
Is there explicit coverage for injection administration?
Yes. Claims 15 and 20 require administration “by injection” in the treatment method.
References (APA)
No external sources were cited because the only material provided is the claim text itself; no patent record, Orange Book listing, or prosecution history was supplied in the prompt.
